First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis

Liver Transpl. 2014 Sep;20(9):1145-8. doi: 10.1002/lt.23918. Epub 2014 Jul 8.

Authors

Benedikt Schaefer¹, Michael Steurer, Bernhard Glodny, Daniel Neureiter, Patrizia Moser, Livia Dorn, Wolfgang Vogel, Heinz Zoller

Affiliation

¹ Gastroenterology and Hepatology, Department of Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

PMID: 24844674
DOI: 10.1002/lt.23918

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Biopsy
Brentuximab Vedotin
Fatal Outcome
Humans
Immunoconjugates / therapeutic use*
Immunosuppressive Agents / therapeutic use
Liver Transplantation / adverse effects*
Lymphoma, Large-Cell, Anaplastic / diagnosis
Lymphoma, Large-Cell, Anaplastic / drug therapy*
Lymphoma, Large-Cell, Anaplastic / etiology
Male
Middle Aged
Remission Induction
Risk Factors
Sepsis / diagnosis
Sepsis / microbiology*
Sepsis / therapy
Time Factors
Tomography, X-Ray Computed

Substances

Antineoplastic Agents
Immunoconjugates
Immunosuppressive Agents
Brentuximab Vedotin